So that’s really the endgame in mind.
Kyle Mikson : Yes. And you touched on all the questions there. Can I just ask about manufacturing? I mean, you didn’t really mention that at all, but is that a bottleneck whatsoever so far? Or are you pretty much good to go on when it comes to supply chain, things like that?
Jeff Hawkins : Yes. No concerns on supply chain. And manufacturing was not a bottleneck in any way to the results in the second quarter.
Kyle Mikson : Okay. Awesome. And then maybe just closing on like a positive comment. Look, it’s good to hear the outbound marketing that’s kind of all systems go, and it sounds like early success there, early kind of like progress. When you kind of crank that up, I mean, are you thinking about going after any new customer types, maybe you’re going to unlock or increase your footprint in nonacademic markets like biotech, maybe just kind of expanding your footprint there, I think that’d be kind of interesting to hear?
Jeff Hawkins : Yes, Kyle, thanks for that question. The way the commercial marketing team is approaching, it’s a mix. Sometimes you’re diving in with a campaign to really look for a specific type of user with specific types of applications within the academic research environment. And other times, the campaigns will be around unlocking new segments, Biotech, as you mentioned, perhaps more industrial settings for antibody QA/QC. So really, the outbound marketing programs are very, very targeted. So we’ll run many of them across these different areas as we try to drive really that specific demand that lines up well to where we’re seeing success in the market.
Operator: The next question comes from Yuan Zhi with B. Riley.
Yuan Zhi: Jeff, a quick follow-up on Kyle’s question. You mentioned the challenge in the implementation front. Can you comment on if the test launch requests from customers or potential customers have changed since 1Q? And then I have a follow-up question.
Jeff Hawkins : Yes. The requests haven’t changed, Yuan. Really what it is, is more you get into the customer’s laboratory and they work through that full workflow from their — from whatever the biological sample type is they selected on up through the sequencing on our platform and ultimately, that analysis and there’s just a very broad range of samples and sample prep methods. I mean ranging everywhere from someone who might isolate a protein in a gel and cut out a band to people using immuno-precipitation kits and other sort of chemistries. So it’s not really that there’s any difference in the request. It’s just each customer has a somewhat unique set of samples and prep methods that we have to work closely with them to optimize in front of the sequencing on the Platinum instrument.
Yuan Zhi: Got it. Thanks for clarifying the technical challenge there. My other question is, can you maybe talk about the poster presentation you had at ASMS? What was challenge on identifying protein and proteoform in that sample in that presentation?
Jeff Hawkins : Yes. At the ASMS conference, that was really a poster to not only demonstrate some of the capabilities of our technology, but really to help for that group of users who are also mass spec users really help them understand how does our technology perform in comparison to mass spec as well as share information around the workflow, the automated analysis that our platform affords a user. So it was really an educational and sort of comparative data study for that — for those users in the mass spec community.
Operator: The next question comes from Swayampakula Ramakanth with H.C. Wainwright.
Swayampakula Ramakanth : Good morning, Jeff and Jeff. Appreciate you taking my questions. So, Jeff, the issues that some of your current customers have flagged during this initial launch. Were they to a specific sample types, is it more universal?
